Inventory increased 25.9%
Inventory changed +25.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$3.0M→$3.8M4 prior comparisons
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Inventory changed +25.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Research & development changed +6.0% from the comparable as-filed period.
Revenue changed +0.1% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.